Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2011

Tronconi Maria Chiara, Sclafani Francesco, Rimassa Lorenza, Carnaghi Carlo, Personeni Nicola, Santoro Armando

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Fatal Outcome

Share to Infusions, Intravenous

Share to Irinotecan

Share to Patient Selection

Source

Identifiers

PMID: 21690469
DOI: 10.1200/JCO.2011.35.5651

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.PMID 21690469Read ↗

Management of Hypersensitivity in Oncology Practice: Risk Stratification, Phenotypic Markers, and Desensitization ProtocolsSemantic proximity Read ↗

[Pharmacological and clinical profile of Cetuximab Injection (Erbitux)].Semantic proximity Read ↗

Adverse Renal Effects of Anticancer Immunotherapy: A ReviewSemantic proximity Read ↗

Fear of Cancer Recurrence in an Era of Personalized Medicine.Semantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

New Serious Safety Warnings of Targeted Anticancer Agents After Their Initial FDA ApprovalSemantic proximity Read ↗

Adverse events induced by immune checkpoint inhibitors.Semantic proximity Read ↗

A Large Single-Hospital Experience Using Drug Provocation Testing and Rapid Drug Desensitization in Hypersensitivity to Antineoplastic and Biological Agents.Semantic proximity Read ↗

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes and management with desensitization.Semantic proximity Read ↗

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read ↗

Evolution of predictive risk factor analysis for chemotherapy-related toxicitySemantic proximity Read ↗

Infusion-Related Reaction Management With Amivantamab for EGFR Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced PractitionersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.